{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:01:09Z","timestamp":1784757669039,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T00:00:00Z","timestamp":1632096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T00:00:00Z","timestamp":1632096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001665","name":"agence nationale de la recherche","doi-asserted-by":"publisher","award":["ANR-10-EQPX-05- 01\/IMAPPI Equipex"],"award-info":[{"award-number":["ANR-10-EQPX-05- 01\/IMAPPI Equipex"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>During anthracycline treatment of cancer, there is a lack for biomarkers of cardiotoxicity besides the cardiac dysfunction. The objective of the present study was to compare [<jats:sup>18<\/jats:sup>F]FDG and [<jats:sup>123<\/jats:sup>I]MIBG (metaiodobenzylguanidine) in a longitudinal study in a doxorubicin-induced cardiotoxicity rat model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Male Wistar Han rats were intravenously administered 3 times at 10\u00a0days\u2019 interval with saline or doxorubicin (5\u00a0mg\/kg). [<jats:sup>123<\/jats:sup>I]MIBG SPECT\/CT (single photon emission computed tomography-computed tomography) and simultaneous [<jats:sup>18<\/jats:sup>F]FDG PET (positron emission tomography)\/7 Tesla cardiac MR (magnetic resonance) imaging acquisitions were performed at 24\u00a0h interval before first doxorubicin \/ saline injection and every 2\u00a0weeks during 6\u00a0weeks. At 6\u00a0weeks, the heart tissue was collected for histomorphometry measurements.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At week 4, left ventricle (LV) end-diastolic volume was significantly reduced in the doxorubicin group. At week 6, the decreased LV end-diastolic volume was maintained, and LV end-systolic volume was increased resulting in a significant reduction of LV ejection fraction (47\u2009\u00b1\u20096% vs. 70\u2009\u00b1\u20093%). At weeks 4 and 6, but not at week 2, myocardial [<jats:sup>18<\/jats:sup>F]FDG uptake was decreased compared with the control group (respectively, 4.2\u2009\u00b1\u20090.5%ID\/g and 9.2\u2009\u00b1\u20090.8%ID\/g at week 6). Moreover, [<jats:sup>18<\/jats:sup>F]FDG cardiac uptake correlated with cardiac function impairment. In contrast, from week 2, a significant decrease of myocardial [<jats:sup>123<\/jats:sup>I]MIBG heart to mediastinum ratio was detected in the doxorubicin group and was maintained at weeks 4 and 6 with a 45.6% decrease at week 6.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This longitudinal study precises that after doxorubicin treatment, cardiac [<jats:sup>123<\/jats:sup>I]MIBG uptake is significantly reduced as early as 2\u00a0weeks followed by the decrease of the LV end-diastolic volume and [<jats:sup>18<\/jats:sup>F]FDG uptake at 4\u00a0weeks and finally by the increase of LV end-systolic volume and decrease of LV ejection fraction at 6\u00a0weeks. Cardiac innervation imaging should thus be considered as an early key feature of anthracycline cardiac toxicity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13550-021-00835-1","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T14:07:02Z","timestamp":1632146822000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["[123I]MIBG is a better early marker of anthracycline cardiotoxicity than [18F]FDG: a preclinical SPECT\/CT and simultaneous PET\/MR study"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1267-0293","authenticated-orcid":false,"given":"Alexandra","family":"Oudot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Courteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Guillemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Vrigneaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Michael","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Brunotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Cochet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Collin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,20]]},"reference":[{"key":"835_CR1","doi-asserted-by":"publisher","first-page":"L19","DOI":"10.1093\/eurheartj\/suaa127","volume":"22","author":"I Bisceglia","year":"2020","unstructured":"Bisceglia I, Cartoni D, Petrolati S. Concepts in cardiac oncology. Eur Heart J Suppl. 2020;22:L19-l23. https:\/\/doi.org\/10.1093\/eurheartj\/suaa127.","journal-title":"Eur Heart J Suppl"},{"issue":"3","key":"835_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.2967\/jnumed.110.082784","volume":"41","author":"LF de Geus-Oei","year":"2013","unstructured":"de Geus-Oei LF, Mavinkurve-Groothuis AM, Bellersen L, Gotthardt M, Oyen WJ, Kapusta L, van Laarhoven HW. Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity. J Nucl Med Technol. 2013;41(3):170\u201381. https:\/\/doi.org\/10.2967\/jnumed.110.082784.","journal-title":"J Nucl Med Technol"},{"key":"835_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1161\/circulationaha.119.042276","volume":"141","author":"VG Zaha","year":"2020","unstructured":"Zaha VG, Meijers WC, Moslehi J. Cardio-immuno-oncology. Circulation. 2020;141:87\u20139. https:\/\/doi.org\/10.1161\/circulationaha.119.042276.","journal-title":"Circulation"},{"key":"835_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111708","volume":"139","author":"PS Rawat","year":"2021","unstructured":"Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother. 2021;139: 111708. https:\/\/doi.org\/10.1016\/j.biopha.2021.111708.","journal-title":"Biomed Pharmacother"},{"key":"835_CR5","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/ejhf.1957","volume":"22","author":"J \u010celutkien\u0117","year":"2020","unstructured":"\u010celutkien\u0117 J, Pudil R, L\u00f3pez-Fern\u00e1ndez T, Grapsa J, Nihoyannopoulos P, Bergler-Klein J, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020;22:1504\u201324. https:\/\/doi.org\/10.1002\/ejhf.1957.","journal-title":"Eur J Heart Fail"},{"key":"835_CR6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/s1470-2045(09)70042-7","volume":"10","author":"R Altena","year":"2009","unstructured":"Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol. 2009;10:391\u20139. https:\/\/doi.org\/10.1016\/s1470-2045(09)70042-7.","journal-title":"Lancet Oncol"},{"key":"835_CR7","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1007\/s12350-019-01671-6","volume":"27","author":"A Soufer","year":"2020","unstructured":"Soufer A, Liu C, Henry ML, Baldassarre LA. Nuclear cardiology in the context of multimodality imaging to detect cardiac toxicity from cancer therapeutics: Established and emerging methods. J Nucl Cardiol. 2020;27:1210\u201324. https:\/\/doi.org\/10.1007\/s12350-019-01671-6.","journal-title":"J Nucl Cardiol"},{"key":"835_CR8","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s12350-018-01566-y","volume":"27","author":"AH Laursen","year":"2020","unstructured":"Laursen AH, Ripa RS, Hasbak P, Kj\u00e6r A, Elming MB, K\u00f8ber L, et al. (123)I-MIBG for detection of subacute doxorubicin-induced cardiotoxicity in patients with malignant lymphoma. J Nucl Cardiol. 2020;27:931\u20139. https:\/\/doi.org\/10.1007\/s12350-018-01566-y.","journal-title":"J Nucl Cardiol"},{"key":"835_CR9","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2967\/jnumed.117.191122","volume":"58","author":"M Bauckneht","year":"2017","unstructured":"Bauckneht M, Ferrarazzo G, Fiz F, Morbelli S, Sarocchi M, Pastorino F, et al. Doxorubicin effect on myocardial metabolism as a prerequisite for subsequent development of cardiac toxicity: a translational (18)F-FDG PET\/CT observation. J Nucl Med. 2017;58:1638\u201345. https:\/\/doi.org\/10.2967\/jnumed.117.191122.","journal-title":"J Nucl Med"},{"key":"835_CR10","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1038\/s41598-019-38986-w","volume":"9","author":"BF Bulten","year":"2019","unstructured":"Bulten BF, Sollini M, Boni R, Massri K, de Geus-Oei LF, van Laarhoven HWM, et al. Cardiac molecular pathways influenced by doxorubicin treatment in mice. Sci Rep. 2019;9:2514. https:\/\/doi.org\/10.1038\/s41598-019-38986-w.","journal-title":"Sci Rep"},{"key":"835_CR11","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1007\/s12350-019-01617-y","volume":"27","author":"J Kim","year":"2020","unstructured":"Kim J, Cho SG, Kang SR, Yoo SW, Kwon SY, Min JJ, et al. Association between FDG uptake in the right ventricular myocardium and cancer therapy-induced cardiotoxicity. J Nucl Cardiol. 2020;27:2154\u201363. https:\/\/doi.org\/10.1007\/s12350-019-01617-y.","journal-title":"J Nucl Cardiol"},{"key":"835_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s12967-018-1670-9","volume":"16","author":"M Sarocchi","year":"2018","unstructured":"Sarocchi M, Bauckneht M, Arboscello E, Capitanio S, Marini C, Morbelli S, et al. An increase in myocardial 18-fluorodeoxyglucose uptake is associated with left ventricular ejection fraction decline in Hodgkin lymphoma patients treated with anthracycline. J Transl Med. 2018;16:295. https:\/\/doi.org\/10.1186\/s12967-018-1670-9.","journal-title":"J Transl Med"},{"key":"835_CR13","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1631\/jzus.B1600257","volume":"17","author":"LJ Shen","year":"2016","unstructured":"Shen LJ, Lu S, Zhou YH, Li L, Xing QM, Xu YL. Developing a rat model of dilated cardiomyopathy with improved survival. J Zhejiang Univ Sci B. 2016;17:975\u201383. https:\/\/doi.org\/10.1631\/jzus.B1600257.","journal-title":"J Zhejiang Univ Sci B"},{"key":"835_CR14","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1007\/s12350-019-01618-x","volume":"27","author":"M Bauckneht","year":"2020","unstructured":"Bauckneht M, Pastorino F, Castellani P, Cossu V, Orengo AM, Piccioli P, et al. Increased myocardial (18)F-FDG uptake as a marker of Doxorubicin-induced oxidative stress. J Nucl Cardiol. 2020;27:2183\u201394. https:\/\/doi.org\/10.1007\/s12350-019-01618-x.","journal-title":"J Nucl Cardiol"},{"key":"835_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1109\/tmi.2020.3024722","volume":"40","author":"A Courteau","year":"2021","unstructured":"Courteau A, McGrath J, Walker PM, Pegg R, Martin G, Garipov R, et al. Performance evaluation and compatibility studies of a compact preclinical scanner for simultaneous PET\/MR imaging at 7 tesla. IEEE Trans Med Imaging. 2021;40:205\u201317. https:\/\/doi.org\/10.1109\/tmi.2020.3024722.","journal-title":"IEEE Trans Med Imaging"},{"key":"835_CR16","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s00280-015-2874-9","volume":"76","author":"BF Bulten","year":"2015","unstructured":"Bulten BF, Verberne HJ, Bellersen L, Oyen WJ, Sabat\u00e9-Llobera A, Mavinkurve-Groothuis AM, et al. Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients. Cancer Chemother Pharmacol. 2015;76:957\u201367. https:\/\/doi.org\/10.1007\/s00280-015-2874-9.","journal-title":"Cancer Chemother Pharmacol"},{"key":"835_CR17","first-page":"2044","volume":"36","author":"I Carri\u00f3","year":"1995","unstructured":"Carri\u00f3 I, Estorch M, Bern\u00e1 L, L\u00f3pez-Pousa J, Tabernero J, Torres G. Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J Nucl Med. 1995;36:2044\u20139.","journal-title":"J Nucl Med"},{"key":"835_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/s1071-3581(96)90022-7","volume":"3","author":"J Lekakis","year":"1996","unstructured":"Lekakis J, Prassopoulos V, Athanassiadis P, Kostamis P, Moulopoulos S. Doxorubicin-induced cardiac neurotoxicity: study with iodine 123-labeled metaiodobenzylguanidine scintigraphy. J Nucl Cardiol. 1996;3:37\u201341. https:\/\/doi.org\/10.1016\/s1071-3581(96)90022-7.","journal-title":"J Nucl Cardiol"},{"key":"835_CR19","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s002590050563","volume":"27","author":"TJ Jeon","year":"2000","unstructured":"Jeon TJ, Lee JD, Ha JW, Yang WI, Cho SH. Evaluation of cardiac adrenergic neuronal damage in rats with doxorubicin-induced cardiomyopathy using iodine-131 MIBG autoradiography and PGP 9.5 immunohistochemistry. Eur J Nucl Med. 2000;27:686\u201393. https:\/\/doi.org\/10.1007\/s002590050563.","journal-title":"Eur J Nucl Med"},{"key":"835_CR20","first-page":"1283","volume":"34","author":"S Wakasugi","year":"1993","unstructured":"Wakasugi S, Fischman AJ, Babich JW, Aretz HT, Callahan RJ, Nakaki M, Wilkinson R, Strauss HW. Metaiodobenzylguanidine: evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy. J Nucl Med. 1993;34:1283\u20136.","journal-title":"J Nucl Med"},{"key":"835_CR21","first-page":"2069","volume":"36","author":"S Wakasugi","year":"1995","unstructured":"Wakasugi S, Inoue M, Tazawa S. Assessment of adrenergic neuron function altered with progression of heart failure. J Nucl Med. 1995;36:2069\u201374.","journal-title":"J Nucl Med"},{"key":"835_CR22","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/ehjci\/jeab007","volume":"22","author":"A Gimelli","year":"2021","unstructured":"Gimelli A, Liga R, Agostini D, Bengel FM, Ernst S, Hyafil F, et al. The role of myocardial innervation imaging in different clinical scenarios: an expert document of the European Association of Cardiovascular Imaging and Cardiovascular Committee of the European Association of Nuclear Medicine. Eur Heart J Cardiovasc Imaging. 2021;22:480\u201390. https:\/\/doi.org\/10.1093\/ehjci\/jeab007.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"835_CR23","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1007\/s00259-017-3828-8","volume":"44","author":"R Kobayashi","year":"2017","unstructured":"Kobayashi R, Chen X, Werner RA, Lapa C, Javadi MS, Higuchi T. New horizons in cardiac innervation imaging: introduction of novel (18)F-labeled PET tracers. Eur J Nucl Med Mol Imaging. 2017;44:2302\u20139. https:\/\/doi.org\/10.1007\/s00259-017-3828-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"835_CR24","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.2967\/jnumed.112.104232","volume":"54","author":"T Higuchi","year":"2013","unstructured":"Higuchi T, Yousefi BH, Kaiser F, G\u00e4rtner F, Rischpler C, Reder S, et al. Assessment of the 18F-labeled PET tracer LMI1195 for imaging norepinephrine handling in rat hearts. J Nucl Med. 2013;54:1142\u20136. https:\/\/doi.org\/10.2967\/jnumed.112.104232.","journal-title":"J Nucl Med"},{"key":"835_CR25","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.2967\/jnumed.115.158493","volume":"56","author":"RA Werner","year":"2015","unstructured":"Werner RA, Rischpler C, Onthank D, Lapa C, Robinson S, Samnick S, et al. Retention kinetics of the 18F-labeled sympathetic nerve PET tracer LMI1195: comparison with 11C-hydroxyephedrine and 123I-MIBG. J Nucl Med. 2015;56:1429\u201333. https:\/\/doi.org\/10.2967\/jnumed.115.158493.","journal-title":"J Nucl Med"},{"key":"835_CR26","doi-asserted-by":"publisher","DOI":"10.1161\/circimaging.115.003584","author":"H Farhad","year":"2016","unstructured":"Farhad H, Staziaki PV, Addison D, Coelho-Filho OR, Shah RV, Mitchell RN, et al. Characterization of the changes in cardiac structure and function in mice treated with anthracyclines using serial cardiac magnetic resonance imaging. Circ Cardiovasc Imaging. 2016. https:\/\/doi.org\/10.1161\/circimaging.115.003584.","journal-title":"Circ Cardiovasc Imaging"},{"key":"835_CR27","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jacc.2018.11.046","volume":"73","author":"C Gal\u00e1n-Arriola","year":"2019","unstructured":"Gal\u00e1n-Arriola C, Lobo M, V\u00edlchez-Tschischke JP, L\u00f3pez GJ, de Molina-Iracheta A, P\u00e9rez-Mart\u00ednez C, et al. Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity. J Am Coll Cardiol. 2019;73:779\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.046.","journal-title":"J Am Coll Cardiol"},{"key":"835_CR28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ultrasmedbio.2007.07.018","volume":"34","author":"RQ Migrino","year":"2008","unstructured":"Migrino RQ, Aggarwal D, Konorev E, Brahmbhatt T, Bright M, Kalyanaraman B. Early detection of doxorubicin cardiomyopathy using two-dimensional strain echocardiography. Ultrasound Med Biol. 2008;34:208\u201314. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2007.07.018.","journal-title":"Ultrasound Med Biol"},{"key":"835_CR29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.etp.2017.01.004","volume":"69","author":"JL O'Connell","year":"2017","unstructured":"O\u2019Connell JL, Romano MM, Campos Pulici EC, Carvalho EE, de Souza FR, Tanaka DM, et al. Short-term and long-term models of doxorubicin-induced cardiomyopathy in rats: a comparison of functional and histopathological changes. Exp Toxicol Pathol. 2017;69:213\u20139. https:\/\/doi.org\/10.1016\/j.etp.2017.01.004.","journal-title":"Exp Toxicol Pathol"},{"key":"835_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.11152\/mu.2013.2066.151.ms1ddc2","volume":"15","author":"M Spivak","year":"2013","unstructured":"Spivak M, Bubnov R, Yemets I, Lazarenko L, Timoshok N, Vorobieva A, et al. Doxorubicin dose for congestive heart failure modeling and the use of general ultrasound equipment for evaluation in rats. Longitudinal in vivo study. Med Ultrason. 2013;15:23\u20138. https:\/\/doi.org\/10.11152\/mu.2013.2066.151.ms1ddc2.","journal-title":"Med Ultrason"},{"key":"835_CR31","first-page":"1529","volume":"34","author":"S Wakasugi","year":"1993","unstructured":"Wakasugi S, Fischman AJ, Babich JW, Callahan RJ, Elmaleh DR, Wilkinson R, Strauss HW. Myocardial substrate utilization and left ventricular function in adriamycin cardiomyopathy. J Nucl Med. 1993;34:1529\u201335.","journal-title":"J Nucl Med"},{"issue":"7","key":"835_CR32","first-page":"1789","volume":"60","author":"OJ Arola","year":"2000","unstructured":"Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res. 2000;60(7):1789\u201392.","journal-title":"Cancer Res"},{"issue":"5","key":"835_CR33","first-page":"842","volume":"45","author":"RJ Bennink","year":"2004","unstructured":"Bennink RJ, van den Hoff MJ, van Hemert FJ, de Bruin KM, Spijkerboer AL, Vanderheyden JL, Steinmetz N, van Eck-Smit BL. Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats. J Nucl Med. 2004;45(5):842\u20138.","journal-title":"J Nucl Med"},{"key":"835_CR34","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jcmg.2019.07.018","volume":"13","author":"JN Upshaw","year":"2020","unstructured":"Upshaw JN, Finkelman B, Hubbard RA, Smith AM, Narayan HK, Arndt L, et al. Comprehensive assessment of changes in left ventricular diastolic function with contemporary breast cancer therapy. JACC Cardiovasc Imaging. 2020;13:198\u2013210. https:\/\/doi.org\/10.1016\/j.jcmg.2019.07.018.","journal-title":"JACC Cardiovasc Imaging"},{"key":"835_CR35","doi-asserted-by":"publisher","first-page":"220","DOI":"10.4329\/wjr.v4.i5.220","volume":"4","author":"C Borde","year":"2012","unstructured":"Borde C, Kand P, Basu S. Enhanced myocardial fluorodeoxyglucose uptake following Adriamycin-based therapy: evidence of early chemotherapeutic cardiotoxicity? World J Radiol. 2012;4:220\u20133. https:\/\/doi.org\/10.4329\/wjr.v4.i5.220.","journal-title":"World J Radiol"},{"key":"835_CR36","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/rlu.0000000000001194","volume":"41","author":"AK Gorla","year":"2016","unstructured":"Gorla AK, Sood A, Prakash G, Parmar M, Mittal BR. Substantial increase in myocardial FDG uptake on interim PET\/CT may be an early sign of adriamycin-induced cardiotoxicity. Clin Nucl Med. 2016;41:462\u20133. https:\/\/doi.org\/10.1097\/rlu.0000000000001194.","journal-title":"Clin Nucl Med"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-021-00835-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-021-00835-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-021-00835-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T14:18:00Z","timestamp":1632147480000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-021-00835-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,20]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["835"],"URL":"https:\/\/doi.org\/10.1186\/s13550-021-00835-1","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,20]]},"assertion":[{"value":"20 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal studies were approved by the accredited Ethical committee (C2ea Grand Campus n\u00b0105), the French ministry of research (authorization #6191) and were carried out in accordance to the legislation on the use of laboratory animals (directive 2010\/63\/EU).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the article for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}